Heartflow Plaque Staging*
The Most Clinically Validated Tool for Plaque-Based Risk Stratification1 

Heartflow Plaque Staging* is
Backed by Evidence.

With outcomes from over 8,000 patients, Heartflow Plaque Staging* is the leading tool for patient risk stratification based on total plaque volume (TPV).1

Nearly
Patients
Stratified to 4 Stages by
Follow-up

Heartflow Plaque Staging*
Personalizes Individual Cardiac Risk
Shown in the FISH&CHIPS 8K clinical study.

Higher TPV stages were associated with statistically significant higher event rates, even after adjusting for stenosis, FFRCT and traditional risk factors.
plaque stage chart

Insights Built for Action in the DECIDE Registry

Medical management recommendations developed by preventive cardiology and CCTA expert consensus are being studied in the DECIDE Registry, the largest prospective registry on Plaque Analysis.2

Overall considerations: Consider GLP1 treatment if BMI>27 kg/m2 | Lifestyle modifications guidance especially in higher stages.

Stage Total Plaque Volume Lipid Biomarkers
Thresholds/Goals
 Medical Management
Currently under clinical evaluation.
Mild‡ 1-100
  • LDL-C: 100 mg/dL
  • Non-HDL: 130 mg/dL
  • Apo-B: 90 mg/dL
  • Statin
  • ± Aspirin
Moderate‡ 101-250
  • LDL-C: 70 mg/dL
  • Non-HDL: 100 mg/dL
  • Apo-B: 70 mg/dL
  • High intensity statin ± PCSK9I ± Bempedoic Acid ± Ezetimibe
  • ± Aspirin
  • If DM: Intensify therapy with GLP1 ± SGLT2I
Severe‡ 251-750
  • LDL-C: 55 mg/dL
  • Non-HDL: 85 mg/dL
  • Apo-B: 60 mg/dL
  • High intensity statin ± PCSK9I ± Bempedoic Acid ± Ezetimibe
  • Aspirin
  • Aggressive BP Rx
  • If DM: Intensify therapy with GLP1 ± SGLT2I
  • If elevated BMI: weight loss treatment
  • If elevated CRP & LDL at target: consider anti-inflammatories
Extensive >750 All as low as can be achieved:
  • LDL-C: <50 mg/dL
  • Non-HDL: <80 mg/dL
  • Apo-B: <50 mg/dL
  • Same as severe
  • ± Colchicine ± Icosapent Ethyl

‡Consider intensifying to next stage if nomogram percentile >50th and/or risk enhancers.3

‡Consider intensifying to next stage if nomogram percentile >50th and/or risk enhancers.3

Measurable Patient Impact

For the first time, modeled outcomes show the risk of CV events could decrease when Heartflow Plaque Staging* guides care.4

18.7mg/dL

Decrease in LDL-C with Plaque Staging* led management

~15%

Suggested decrease in risk of cardiac events based on average LDL-C decrease2,5

18.7mg/dL

Decrease in LDL-C with Plaque Staging* led management.2,5

~15%

Expected decrease in risk of cardiac events based on average LDL-C decrease.2,5